Riskpilot← Back to searchSign inGet full accessOVERSKUDDKLINIKKEN AS
ASActiveOrg 813579022Hoslebakken 5, 1362 HosleMedical specialists activities · NACE 8622Est. 20140 employeesoverskuddklinikken.no
Revenue 2024
NOK 767K
+39% vs 2023
EBITDA margin
7.8%
+4196% vs 2023
Equity ratio
-7.4%
Financial strength
Net profit 2024
NOK 60K
+4065% vs 2023
| Revenue | NOK 767K | +39% |
| EBITDA | NOK 60K | +4196% |
| Net profit | NOK 60K | +4065% |
| Total assets | NOK 18K | -39% |
| Equity | NOK -1K | +98% |
| Employees | 0 | — |
Legal name
OVERSKUDDKLINIKKEN AS
Org number
813579022
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
6. mai 2014
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Utgår
Company purpose
Legetjenester, helsetjenester samt andre produkter/tjenester som naturlig hører sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, og kjøp og salg av aksjer eller annen måte å gjøre seg interessert i andre foretak.
Address
Hoslebakken 5, 1362 Hosle
Website
overskuddklinikken.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 840 | 28 | 108 | 551 | 767 |
| Staff expenses | −0 | −0 | −0 | −0 | −4 |
| EBITDA | 18 | −43 | −30 | 1 | 60 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 18 | −43 | −30 | 1 | 60 |
| Net financials | −3 | −2 | −3 | 0 | 0 |
| Profit before tax | 15 | −45 | −33 | 1 | 60 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 15 | −45 | −33 | 1 | 60 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 83 | 10 | 15 | 29 | 18 |
| Equity | 15 | −30 | −63 | −61 | −1 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 68 | 40 | 77 | 90 | 19 |
| Total debt | 68 | 40 | 77 | 90 | 19 |
EBITDA margin
7.8%
This company
15.8%
Market median
-51% vs market
20202024
Equity ratio
-7.4%
This company
38.2%
Market median
-119% vs market
20202024
Return on equity
6002100.0%
This company
18.4%
Market median
+32620009% vs market
20202024
Net profit margin
7.8%
This company
8.1%
Market median
-4% vs market
20202024
Asset turnover
43.68×
This company
1.12×
Market median
+3800% vs market
20202024
Debt / equity
14.60×
This company
0.62×
Market median
-2255% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AK Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
LW Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 95% | 95% | 2022 | |
| Company | 5% | 5% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Holjo Invest As
OVERSKUDDKLINIKKEN AS Board members of OVERSKUDDKLINIKKEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Kristian Stormo | Chief Executive Officer | 0 companies |
| Lene Wium | Chief Executive Officer | 0 companies |
| Jarle Karsten Holt | Chairman | 0 companies |